AI Medical Devices Cleared Without Outcome Testing
A new study reveals that the vast majority of AI-based medical devices authorized by the FDA have not undergone rigorous testing for patient health outcomes. Researchers warn that the current regulatory framework prioritizes speed over clinical evidence, potentially exacerbating healthcare disparities.
Why it matters
The lack of outcome-based testing for AI in medicine poses significant risks to patient safety and the equitable delivery of healthcare services.
A new analysis shows that, of 1,357 artificial intelligence (AI)-based medical devices authorized by the U.S. Food and Drug Administration (FDA) for use in patient care, only three had been tested on whether they actually improve patients' health. Rawan Abulibdeh of the University of Toronto, Canada, and colleagues present these findings in the open access journal PLOS Digital Health on August 19, 2026.
New AI devices increasingly inform clinical care, such as systems that aid surgical planning, calculate cardiovascular risks, and guide interpretation of mammograms and other imaging. In order to be authorized for use in the U.S., AI devices typically only need to show "substantial equivalence" to an existing authorized device, and developers are not required to demonstrate whether new AI devices help people live healthier lives - with benefits shared equitably across diverse subgroups.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in